Medical Condition News

RSS

DNp63a protein employs epigenetics to keep cancer cells alive

Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.

27 Sep 2012

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Hatch seeks more details from the Obama administration about federal exchanges

Sen. Orrin Hatch, R- Utah, charged that states can't make decisions about whether to pursue their own health insurance exchanges or to rely on the federal fallback version unless they have more information.

27 Sep 2012

NYU Langone creates new groundbreaking collaboration in autism research

NYU Langone Medical Center announced today the creation of a new groundbreaking collaboration in autism research. The Autism Brain Imaging Data Exchange (ABIDE) is a database of brain scans from more than 15 leading international research institutions and academic medical centers.

27 Sep 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

MicroRNA processing in fat tissue plays a major role in aging and stress resistance

As part of their ongoing research investigating the biology of aging, the greatest risk factor for type 2 diabetes and other serious diseases, scientists at Joslin Diabetes Center have identified a new factor - microRNA processing in fat tissue - which plays a major role in aging and stress resistance.

27 Sep 2012

KSU creates simple blood test that can accurately detect lung and breast cancer’s early stages

Researchers at Kansas State University have developed a simple blood test that can accurately detect the beginning stages of cancer.

27 Sep 2012

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

27 Sep 2012

STENTYS announces European commercial release of new Self-Apposing stent technology

STENTYS, a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today the European commercial release of an enhanced stent-delivery system for its Self-Apposing stent.

27 Sep 2012

Stealth Therapeutics announces first implantation of Invisiport device

Stealth Therapeutics Inc. announced today that its Invisiport has been implanted in a patient for the first time.

27 Sep 2012

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

New understanding about functionality of CFTR protein

CFTR is an important protein that, when mutated, causes the life-threatening genetic disease cystic fibrosis. A study in The Journal of General Physiology (JGP) details how an accidental discovery has provided new understanding about CFTR functionality.

27 Sep 2012

Study finds increase in number of total knee replacements among U.S. Medicare population

Total knee replacement is a very common and safe surgery that's used to relieve severe pain and disability caused by knee osteoarthritis, and to improve patients' quality of life. However, it's also very expensive at approximately $15,000 per procedure. With an estimated 600,000 total knee replacements performed annually in the United States, the aggregate annual cost for total knee replacement (also known as total knee arthroplasty or TKA) is $9 billion.

27 Sep 2012

Loyola now offers sacral nerve stimulation for patients with fecal incontinence

Fecal incontinence, or the inability to control the bowels, is a highly underreported and stigmatized condition, according to colorectal surgeons at Loyola University Health System (LUHS).

27 Sep 2012

Go Daddy donates $10,000 for Scottsdale Healthcare Cancer Center fundraiser

GoDaddy.com, the world's largest provider of Web hosting and domain name registrations, is donating $10,000 to help cancer patients and kick-start fundraising for the 4th annual Scottsdale Healthcare Rob Moy Memorial Motorcycle Run.

27 Sep 2012

Accera to sponsor National Memory Screening Day of Alzheimer's Foundation of America

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that it is a silver sponsor of the Alzheimer's Foundation of America's (AFA) National Memory Screening Day (NMSD) on November 13, 2012 during National Alzheimer's Disease Awareness Month.

27 Sep 2012

CeQur completes PaQ Insulin Delivery Device clinical study on type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ Insulin Delivery Device.

27 Sep 2012

Henry Ford Hospital opens new Center for Cancer Surgery

With more patients seeking cancer treatment – especially surgery – than ever before, Henry Ford Hospital has opened the new Center for Cancer Surgery.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

CTCA at Midwestern named Certified Quality Breast Center of Excellence

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) has been recognized by the National Quality Measures for Breast Centers Program (NQMBC) as being among the top centers in the country for providing quality breast cancer care.

27 Sep 2012

Medical Condition News

DNp63a protein employs epigenetics to keep cancer cells alive

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Hatch seeks more details from the Obama administration about federal exchanges

NYU Langone creates new groundbreaking collaboration in autism research

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

MicroRNA processing in fat tissue plays a major role in aging and stress resistance

KSU creates simple blood test that can accurately detect lung and breast cancer’s early stages

Pfizer, Bristol-Myers Squibb report FDA acknowledgement of ELIQUIS NDA resubmission

STENTYS announces European commercial release of new Self-Apposing stent technology

Stealth Therapeutics announces first implantation of Invisiport device

Karolinska Institutet scientists discover new approach to treat type II diabetes

New understanding about functionality of CFTR protein

Study finds increase in number of total knee replacements among U.S. Medicare population

Loyola now offers sacral nerve stimulation for patients with fecal incontinence

Go Daddy donates $10,000 for Scottsdale Healthcare Cancer Center fundraiser

Accera to sponsor National Memory Screening Day of Alzheimer's Foundation of America

CeQur completes PaQ Insulin Delivery Device clinical study on type 2 diabetes

Henry Ford Hospital opens new Center for Cancer Surgery

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

CTCA at Midwestern named Certified Quality Breast Center of Excellence

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News